Nab-paclitaxel: a bright new SPARC in taxane therapy of cancer (editorial)

- Ackland, Stephen P., Bull, James M., Boyle, Frances M.

Dose intensity in anthracycline-based chemotherapy for metastatic breast cancer: mature results of the randomised clinical trial ANZ 9311

- Ackland, Stephen P., Gebski, V., Forbes, J. F., Coates, A. S., Zdenkowski, N., Wilson, A., Green, M., Tees, S., Dhillon, H., Van Hazel, G., Levi, J., Simes, R. J.

Oncology patients overwhelmingly support tissue banking

- Bryant, Jamie, Sanson-Fisher, Rob, Fradgley, Elizabeth, Regan, Timothy, Hobden, Breanne, Ackland, Stephen P.

Collaborative patient-centered quality improvement: a cross-sectional survey comparing the types and numbers of quality initiatives selected by patients and health professionals

- Fradgley, Elizabeth A., Paul, Christine L., Bryant, Jamie, Collins, Nicolas, Ackland, Stephen P., Bellamy, Douglas, Levi, Christopher R.

A simple HPLC method for plasma level monitoring of mitotane and its two main metabolites in adrenocortical cancer patients

- Garg, Madhu B., Sakoff, Jennette A., Ackland, Stephen P.

Pyridoxine to protect from oxaliplatin-induced neurotoxicity without compromising antitumour effect

- Garg, Madhu B., Ackland, Stephen P.

Fixed-dose-rate gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas

- Goldstein, David, Gainford, M Corona, Miller, Danielle, Shannon, Jenny, Brown, Chris, Tebbutt, Niall, Ackland, Stephen P., van Hazel, Guy, Jefford, Michael, Abdi, Ehtesham, Selva-Nayagam, Sid, Gebski, Val

Norcantharimides, synthesis and anticancer activity: synthesis of new norcantharidin analogues and their anticancer evaluation

- Hill, Timothy A., Stewart, Scott G., Ackland, Stephen P., Gilbert, Jayne, Sauer, Benjamin, Sakoff, Jennette A., McCluskey, Adam

Heterocyclic substituted cantharidin and norcantharidin analogues-synthesis, protein phosphatase (1 and 2A) inhibition, and anti-cancer activity

- Hill, Timothy A., Stewart, Scott G., Sauer, Benjamin, Gilbert, Jayne, Ackland, Stephen P., Sakoff, Jennette A., McCluskey, Adam

Norcantharidin analogues: synthesis, anticancer activity and protein phosphatase 1 and 2A inhibition

- Hill, Timothy A., Stewart, Scott G., Gordon, Christopher P., Ackland, Stephen P., Gilbert, Jayne, Sauer, Benjamin, Sakoff, Jennette A., McCluskey, Adam

Dihydropyrimidine dehydrogenase gene variants for predicting grade 4-5 fluoropyrimidine-induced toxicity: FUSAFE individual patient data meta-analysis

- Le Teuff, Gwénaël, Cozic, Nathalie, Largiadèr, Carlo R., Marinaki, Anthony, Jennings, Barbara A., Wettergren, Yvonne, Di Paolo, Antonello, Gross, Eva, Budai, Barna, Ackland, Stephen P., van Kuilenburg, André B. P., Mcleod, Howard L., Boyer, Jean-Christophe, Milano, Gérard, Thomas, F, Loriot, M-A, Kerr, D, Schellens, JHM, Laurent-Puig, P, Shi, Q, Pignon, J-P, Etienne-Grimaldi, M-C, Boige, Valérie, Diasio, Robert b., Taieb, Julien, Meulendijks, Didier, Palles, Claire, Schwab, Matthias, Deenen, Maarten

Cantharidin analogues: synthesis and evaluation of growth inhibition in a panel of selected tumour cell lines

- McCluskey, Adam, Ackland, Stephen P., Bowyer, Michael C., Baldwin, Monique L., Garner, James, Walkom, Cecilia C., Sakoff, Jennette A.

Cantharimides: a new class of modified cantharidin analogues inhibiting protein phosphatases 1 and 2A

- McCluskey, Adam, Walkom, Cecilia, Bowyer, Michael C., Ackland, Stephen P., Gardiner, Emma, Sakoff, Jennette A.

The impact on health-related quality of life in the first 12 months: a randomised comparison of preoperative short-course radiation versus long-course chemoradiation for T3 rectal cancer (Trans-Tasman Radiation Oncology Group Trial 01.04)

- McLachlan, Sue-Anne, Fisher, Richard J., MacKay, John, Ngan, Samuel Y., Zalcberg, John, Solomon, Michael, Burmeister, Bryan, Goldstein, David, Leong, Trevor, Ackland, Stephen P., McKendrick, Joseph, McClure, Bev

Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group Trial 01.04

- Ngan, Samuel Y., Burmeister, Bryan, McKendrick, Joseph, Leong, Trevor, Hartopeanu, Cris, Zalcberg, John, Mackay, John, Fisher, Richard J., Solomon, Michael, Goldstein, David, Joseph, David, Ackland, Stephen P., Schache, David, McClure, Bev, McLachlan, Sue-Anne

Current opinion on optimal treatment for colorectal cancer

- Price, Timothy J., Segelov, Eva, Shapiro, Jeremy D., Burge, Matthew, Haller, Daniel G., Ackland, Stephen P., Tebbutt, Niall C., Karapetis, Christos S., Pavlakis, Nick, Sobrero, Alberto F., Cunningham, David

Serine/threonine protein phosphatase inhibition enhances the effect of thymidylate synthase inhibition

- Sakoff, Jennette A., Howitt, Ian J., Ackland, Stephen P., McCluskey, Adam

Synthesis and biological evaluation of norcantharidin analogues: towards PP1 selectivity

- Stewart, Scott G., Hill, Timothy A., Gilbert, Jayne, Ackland, Stephen P., Sakoff, Jennette A., McCluskey, Adam

Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer

- Stockler, Martin R., Harvey, Vernon J., Gainford, M. Corona, Fong, Akiko, Paksec, Lisa, Sourjina, Tatiana, Zannino, Diana, Gebski, Val, Simes, R. John, Forbes, John F., Coates, Alan S., Francis, Prudence A., Byrne, Michael J., Ackland, Stephen P., Fitzharris, Bernie, Van Hazel , Guy, Wilcken, Nicholas R. C., Grimison, Peter S., Nowak, Anna K.

Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study

- Tebbutt, Niall C., Wilson, Kate, Forgeson, Garry, Cunningham, David, Saunders, Mark P., Stockler, Martin R., Chua, Yujo, Zalcberg, John R., Simes, R. John, Price, Timothy J., Gebski, Val J., Cummins, Michelle M., Zannino, Dianna, van Hazel, Guy A., Robinson, Bridget, Broad, Adam, Ganju, Vinod, Ackland, Stephen P.